Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?

• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Montserrat, Emili [VerfasserIn]
• Titel: Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?
• Institutionen: European Group for Blood and Marrow Transplantation [AuftraggeberIn]
• Verf.angabe: Peter Dreger, Emili Montserrat, on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC)
• E-Jahr: 2015
• Jahr: 5 February 2015
• Umfang: 6 S.
• Fussnoten: Gesehen am 29.06.2020
• Titel Quelle: Enthalten in: Current hematologic malignancy reports
• Ort Quelle: Philadelphia, Pa. : Current Science, 2006
• Jahr Quelle: 2015
• Band/Heft Quelle: 10(2015), 1, Seite 59-64
• ISSN Quelle: 1558-822X
• DOI: doi:10.1007/s11899-014-0242-1
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1702836983

Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnormalities). Currently, new and highly effective therapeutic agents targeting BCR-mediated intracellular signal transduction have been incorporated into the CLL treatment armamentarium. These signal transduction inhibitors (STI) will change the algorithms of high-risk CLL (HR-CLL) management. Despite the limited body of evidence, there is sufficient rationale for withholding alloHSCT in patients with 17p-/TP53mut CLL in first remission. In contrast, the perspectives of patients with relapsed 17p-/TP53mut CLL remain uncertain even if responding to STI. The same accounts for patients with HR-CLL progressing under STI. In both scenarios, it is reasonable to consider alloHSCT, ideally after response to alternative STI regimens.